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Bioactive peptides fermented milk is very potential as functional food 
products for health. The aim of this study is to analyze the inhibition activity 
of Angiotensin Converting Enzyme and kefir whey amino acid profile and 
IC50. The design being applied is a comprehensive random design with five 
treatments (fermentation time 0, 3, 6, 9 and 12 days) and 3 replications. ACE 
inhibition indicators include ACE inhibition with IC50, protein, peptide 
concentration, total proteolytic, and amino acid profiles. The results show 
that ACE inhibition activity ranges from 35.94 - 66.67% with peptide levels 
of 872.80 - 1084.74 mg/mL and IC50 of 65.48 µg/mL, and contained 
hydrophobic amino acids which functioned for ACE inhibition. The 
conclusion of this study that the highest ACE inhibition is obtained at 0 day 
of fermentation with inhibition ability (IC50) of 65.48 µg/mL and functioning 
as nutraceuticals food. 
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1.  Introduction 
 
The finding of Angiotensin Converting Enzyme (ACE) inhibition of fermented milk peptides orally is very 
important in inhibiting hypertension. Inhibition of hypertension, usually using drugs that have side effects, coughing, 
taste disorders, and skin rashes (Qian et al., 2007). Therefore ACE inhibition can be considered as a useful approach 
in dealing with blood pressure problems. 
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Angiotensin Converting Enzyme (ACE) is an enzyme that catalyzes the conversion of angiotensin I decapeptide 
to angiotensin II octapeptide in the Renin-Angiotensin System (RAS) that regulates blood pressure (Riordan, 2003). 
ACE inhibition is an inhibition of ACE enzymes by bioactive compounds which can reduce blood pressure in 
humans. This bioactive compound is found in milk. But it has not been able to function optimally as a functional 
food. Therefore, the potential of functional food is very necessary to improve this functional property, one of which 
is caused by the help of microorganisms. 
Kefir whey is a transparent yellow fermented milk drink, made by fermented milk with kefir seeds, then 
incubation at 25-27 0C ± 24 hours (Ot'es and Cagindi, 2003) so that a transparent liquid and separate curd are formed 
separately. Fanrworth (2005) reported that in kefir grains containing lactic acid bacteria (LAB) and khamir which 
work in a symbiotic mutualism. Liu et al., (2010) reported that this bacteria is very important in the process of milk 
fermentation to increase the production of bioactive peptides which have the potential to lower blood pressure 
through inhibition of Angiotensin Converting Enzyme (ACE inhibitors). The same researcher also reported that the 
type of bacteria used as a starter will greatly affect the type of peptide produced. 
Kefir whey is thought to have the same function as kefir because kefir whey is a liquid, so the components in 
kefir are dissolved in whey. This condition is in accordance with the explanation of LeBlanc et al. (2004) that 
bioactive peptides dissolve in water so that they are thought to be components of dissolved protein in the transparent 
kefir liquid. This is the reason that kefir whey still has high economic value. However, the potential of kefir whey as 
an ACE inhibitor during storage, little information is obtained, because the ACE inhibitory ability correlates with the 
number of LAB and metabolites produced. The purpose of this study is to analyze the ability of kefir whey, the 
highest ACE inhibitor with IC50 during fermentation. The success of this research is a benchmark for increasing food 
potential as nutraceuticals food. 
 
 
2.  Materials and Methods 
 
Material 
 
The main materials in this study are 15 liters of fresh cow skim milk and kefir seeds as a starter. The chemicals 
used in this study, the media Mann Rogosa Shape Agar (MRSA), skim Agar, Pepton Water Buffer (BPW), alcohol, 
aquades, HCL, and biuret solution. The main equipment in this study are ACE KIT-WST, micro Kjehldal, centrifius, 
spectrophotometer, microplate reader, incubator, petri dish, refrigerator, autoclave, oven, and pipette. 
 
 
Metode 
 
This study applies a Completely Randomized Design (CRD) with five storage treatments (0, 3, 6, 9 and 12 days) 
with 3 replications (Stell and Torrie, 1993). 
 
 
Research Procedure 
 
Preparation of the main tools, such as a petri dish, test tube, pipette, Erlenmeyer, measuring cup is by autoclave 
sterilizing at 1210 C ± 30 minutes. 
Preparation of the main chemicals, such as MRSA, is by means of weighing 52 grams, then adding 1000 mL of 
distilled water and heating it so that it is homogeneous. Furthermore, it was sterilized by autoclaving at a temperature 
of 121 0 C ± 15 minutes (Swanson et al., 1993). 
The procedure of making Kefir whey follows the Ot’es and Cagindi (2003) method by means of milk being 
pasteurized to 850 C ± 30 minutes then cooled and fermented with kefir grains at a temperature of 25 – 270 C ± 24 
hours. When the kefir is formed, there are two layers:   the curd and liquid. Then they are separated so that a 
transparent yellow liquid is obtained which is called kefir whey. Kefir whey was stored in a refrigerator at 40 C with 
storage times of 0, 3, 6, 9 and 12 days. 
The variables in this study, ACE  kefir whey activity was analyzed by ACE-WST KIT (Nakamura et al., 1995), 
protein, following the AOAC (2005) method and peptide content with the Biuret method (Brunelli and Waino, 
1949), total proteolytic LAB according to the method of Swanson et al., (1993) 
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3.  Results and Discussions 
 
The results showed that the ACE inhibitory activity and the quality of kefir whey fermented for 0, 3, 6, 9 and 12 
days can be seen in Table 1. Amino acid profile of kefir whey with the highest ACE inhibition on 0 days 
fermentation in Table 2 
 
Table 1 
Inhibition Activity of ACE and the quality of kefir whey skim milk which is fermented by kefir seed during its 
storage 
 
Variable 
Treatment (day) 
0 3 6 9 12 
Inhibition  
ACE (%) 
Protein (%) 
Total BAL 
Proteolytic 
(cfu/mL) 
Peptide 
(µg/mL) 
 
66.67a 
 
1.58b 
4.4x103 a 
 
 
 
1084.74a 
54.84b 
 
1.52b 
3.1x103a 
 
 
 
995.11b 
35.49c 
 
1.37a 
5.5x103a 
 
 
 
872.88c 
39.79c 
 
1.39a 
7.2x103a 
 
 
 
1066.95a 
38.79c 
 
1.37a 
2.0x101b 
 
 
 
869.18c 
Description: different superscripts on the same line show a significant difference (P<0.05) 
 
 
3.1 ACE Inhibition  
 
ACE inhibition is an inhibition of the ACE enzyme that causes hypertension by blocking the change of 
angiotensin I to angiotensin II, which is a strong vasoconstrictor that causes hypertension (Liu et al., 2010, Korhonen 
and Pihlanto 2006). 
Fermentation duration of 0, 3 and 6 days (P <0.05) decreased ACE kefir whey inhibitory activity. However, 6 - 
12 days of fermentation were no a significant difference (P> 0.05). The highest ACE inhibition is obtained on 0 
fermentation days with IC50 is 65.49 µg/mL. The high ACE inhibition is due to the activity of Lactobacillus and 
Leuconostoc which a proteolytic LAB, hydrolyzing proteins into oligopeptides, peptides during fermentation 
(Fanrworth, 2005). This occurs at the beginning of fermentation because LAB is in a position on the surface of kefir 
seeds, while khamir is on the inside (Graciela et al., 2010) and peptides formed at 0 days are thought to be 
metabolites that have a function as ACE inhibitors. These results are similar to those reported by Febrisiantosa et al, 
(2013) that ACE inhibition correlates with the number of peptides. However, ACE inhibition on fermentation 
duration of 6 - 12 days was lower (P> 0.05), although it was followed by an increase in the number of the proteolytic 
labs at 9 days. When viewed from the peptide concentration, there was an increase in 9 days, i.e. 1066.95 mg / mL 
but ACE inhibition was low, then at 12 days, there was a decrease (Table 1). Low ACE inhibition, presumably 
produced metabolites, only partly as a peptide that functions as a hypertensive inhibitor, because Korhonen and 
Pihlanto (2006) reported that peptides have different functions, namely as antihypertensive, opioid, antimicrobial and 
immune systems. Miller et al., (2007) reported that whey still has bioactive components, especially from whey 
protein. Ebringer et al. (2008), a source of peptides from whey, namely β-lactoglobulin and α-lactalbumin have 
functioned as a source of antihypertensive peptides. ACE inhibition in this study is different from that produced by 
Febrisiantosa et al, (2013) that is equal to 73.07% with raw ingredients of fermented whey cheese with kefir grains 
The mechanism of ACE inhibition by peptide whey kefir as an inhibitor, due to the peptide produced by LAB, 
will inhibit the ACE enzyme as a precursor that converts Angiotensin I to II Angiotension, which is a strong 
constructor that triggers aldosterone synthesis and release, which causes increased blood pressure, narrowing of 
blood vessels (Liu et al, 2010). ACE enzyme inhibition by inhibitory peptides is initiated by the binding of ACE-
inhibiting peptides to the three active sides of the ACE enzyme. Wijesekara and Kim (2010) this binding peptide 
changes the composition of the protein so that there is no interaction between angiotensin I and the active side of the 
ACE enzyme. It was also reported that by binding to the peptides on the three active sides of the ACE enzyme, 
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namely C-terminal, plays an important role in ACE inhibitors, which binds to hydrophobic amino acids. Nakamura 
et al. (1995), Korhonen and Pihlanto (2006) report that the functional properties of ACE inhibitors are largely 
determined by the amino acid composition of bioactive peptides derived from milk protein namely Val-Pro-Pro or 
Ileu-Pro-Pro. However, the amino acid sequence in the C-terminal is only a control of the inhibiting peptide, because 
this sequence is still learned. Besides that, Madureira et al. (2010) stated the type of BAL used as a starter will 
determine the type of peptide. 
 
 
3.2 Protein level  
 
The highest protein levels were found in the fermentation period of 0 days which was 1.58% and the lowest was 
at 12 days, which was 1.37%. The low protein content in all treatments was caused, the sample used in this study was 
kefir whey, in the form of transparat liquid, the result of separation with curd kefir (Figure 2.) so that part of the 
biomass was still bound to the kefir grain matrix or polysaccharide (Graciela  et al., 2010).  However, LeBlanc et al., 
(2004) reported that kefir granules 
However, LeBlanc et al., (2004) reported were diss dissolved in water, so that in kefir whey still contain kefir 
protein content in curd kefir consumption was consumption during storage up to 12 days was 4.74- 4.08%. 
Compared to SNI, it was still in standard. BSN-SNI (2009) that the minimum limit of kefir protein is 1%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Kefir Whey 
 
In the process of fermentation of milk by kefir grains, Fanworth (2005) reported that the activity of LAB 
(Lactobacillus and Leuconostoc), begins with the degradation of lactose into lactic acid. Lactic acid is formed, 
coagulating proteins so that curd occurs. Then this bacterium with its proteolytic enzyme (intracellular peptidase 
enzyme) hydrolyzes proteins into oligopeptides, tri-di peptides, and amino acids. Pihlanto et al., (2000) reported that 
the results of this hydrolysis were first used as nutrients by the LAB and the remaining potential as a functional food 
for health. This situation stimulates Streptococcus growth. The presence of Streptococcus, causes the atmosphere to 
become acidic and can inhibit its growth. However, it actually stimulates Lactobacillus to regrow so that the total 
proteolytic LAB is currently low. 
The high levels of this protein are also caused by the total proteolytic BAL that forms a clear zone in its growth in 
petri dishes (Figure 2). This indicates a higher level of protein biodegradation (Table 1), thus causing an increase in 
biomass from metabolic LAB results. Acidity, a decrease in protein levels was followed by a total proteolytic BAL, 
although it was not statistically significant (P <0.05), because Farnworth (2005), states that bioactive component in 
kefir is kefir seed microbes, its metabolites (polysaccharides, peptides) which have potential health. 
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Figure 2. Zona of LAB proteolitik on skim agar 
 
3.3 Total BAL Proteolytic 
 
The results of variance showed that the amount of proteolytic LAB with fermentation duration of 0 - 9 days was 
not significant (P> 0.05), but in the 12th fermentation was significantly (P <0.05) decreased. This indicates that the 
fermentation duration of 0 - 9 days has not shown an increase in the number of proteolytic bacteria, assumed to enter 
the stationary phase. Mainvifle (2006) reported that in the stationary phase there was a decrease in the number of 
Streptococcus, due to the acid produced (the higher the fermentation time, 2.52 - 3.77), but Lactobacillus growth 
occurred. While Lund and Eklund (2000) reported that LAB grew optimally at pH 4.82 - 4.39. However, there was a 
decrease in the amount of proteolytic BAL in the 12-day fermentation period, due to the growth of molds. 
 
 
3.4 Kadar Peptide 
 
The level of kefir whey peptide is the result of biodegradation of BAL, an especially proteolytic group so that all 
processes during fermentation are affected by its activity and nutrient content in the product. Peptides obtained in 
this study were significant (P <0.05) influenced by fermentation time (Table 1). The high levels of peptide were 
found in the fermentation period 0 day. This is due to the process of fermentation of milk by proteolytic lactic acid 
bacteria causing an acidic atmosphere. Acidic conditions besides causing coagulation of proteins, further hydrolysis 
of proteins occurs by proteolytic enzymes to oligopeptide and peptide. 
In the fermentation period of 3 - 9 days there was a decrease in peptide levels, due to a decrease in proteolytic 
lactic acid bacteria (Streptococcus), while at day 9 there was an increase in peptide levels (P <0.05). It is caused by 
the increase of Lactobacillus (Farnworth, 2005). Meanwhile on the 12 days, the decrease of peptide level occurs, 
because it is dominated by the growth of molds. Nurhayati et al., (2013) stated that the acidity causes a positive ion 
exchange with negative ions in the acid, so that the breakdown of the protein structure results in the breakdown of 
the peptide bond chain into peptides with shorter chain amino acids. 
 
 
3.5 Amino Kefir Whey Acid Profile 
 
The amino acid profile shown is the amino acid from whey kefir with the highest ACE inhibition on 0 days of 
fermentation and also displayed 3 days of fermentation time and milk can be seen in Table 2. 
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Table 2  
Profile of Amino Acid Milk, Kefir Whey with Fermentation Length 
0 and 3 days 
 
Amino Acid Milk Whey 0 day Whey 3 days 
Serine 1607.22 - <830.17 
Glutamic acid 6559.33 834.75 702.92 
Phenylalanine 1486.66 191.57 173.60 
Isoleucine 1537.70 223.80 208.65 
Valine 1723.38 222.74 203.83 
Alanine 1026.18 373.33 369.55 
Arginine 907.54 <153.15 <153.15 
Glysine 618.36 <402.00 <402.00 
Lysine 2909.85 393.11 359.22 
Aspartate acid 2220.37 <399.37 <399.37 
Leucine 2894.32 381.18 339.39 
Tyrosin 1242.26 <222.88 <222.88 
Proline 2616.84 352.30 274.68 
Threonine 1385.21 294.74 250.63 
Histidine 736.58 <136.06 <136.06 
Metionine 712.70 87.17 61.02 
Sistine 161.24 - - 
Tryptopan 258.56 <56.14 <56.14 
   
The results of analysis of the content of amino acid kefir whey with fermentation time of 0, 3 days and milk, with 
HPLC, consists of hydrophobic amino acids (Isoleucine, Alanine, Leucine, Proline, Valine, Glycine) and hydrophilic 
(Serine, Glutamic Acid, Aspartate Acid, Threonine, Methionine,). However, it differs in the ability to inhibit ACE. 
This difference is thought to be caused by the short and length of the peptide chain. Wikandari and Yuanita (2014) 
reported that peptides have the potential as antihypertensive agents are short-chain with 2 - 12 amino acid residues 
and are strongly influenced by fermentation duration. The content of amino acids is very closely related to ACE 
inhibition. Qian et al., (2007), reported that ACE inhibition occurs, if there is a hydrophobic amino acid peptide 
inhibiting bond with three active ACE enzymes in C-terminal. Meanwhile, the hydrophilic amino acid, which has 
ACE inhibition, is very weak because it is not compatible with the active side of the ACE enzyme. Abubakar (2014) 
reported the results of his research that ACE inhibition occurs if there are several proline amino acid residues in the 
peptide chain) 
 
 
4.  Conclusion 
 
The conclusion of this study that: 
a) Inhibition activity of Angiotensin Converting Enzyme kefir whey is obtained on 0 fermentation days with 
IC50 is  65.48 µg/mL                      
b) Profile of amino acids that function to inhibit ACE including hydrophobic  
c) Amino acids with peptide levels 1084.74 mg/mL.   
d) Kefir whey functions as nutraceuticals food. 
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